Pharmacokinetics of Micafungin in Patients Intensive Care Unit
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In this trial, our goal is to determine the pharmacokinetics of micafungin in a non-selected
cohort of patients with suspected or proven invasive fungal infections. Patients will receive
micafungin for the period necessary to achieve clinical and / or mycological cure. An attempt
will be made to have 2 PK curves, one full and one limited sampling on days 3 (n=9) and 7
(n=5). Furthermore, we will be able to determine intra-individual variability. On non-PK
days, trough samples will be taken to determine the time to steady state. All samples will be
taken just prior to the morning dose of micafungin. All infusion rates will be according to
the SPC label information. Patients are considered to be evaluable if at least the first PK
curve has been completed. Two moments of PK analysis will enable us to determine whether
there is an increase over time in exposure if steady state has not been reached.